IPP Bureau
New law to regulate drugs and medical devices soon
By IPP Bureau - September 09, 2021
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
Equipment shortage and overpriced APIs pinch the pharma industry
By IPP Bureau - September 09, 2021
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Zydus Cadila gets US FDA approval for antidepressant tablets
By IPP Bureau - September 09, 2021
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Merck’s KEYTRUDA receives China approval for Esophageal cancer
By IPP Bureau - September 09, 2021
The medicine is now approved for eight indications across five different types of cancer in China.
Sandoz enters agreement for oncology biosimilar medicine bevacizumab
By IPP Bureau - September 09, 2021
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
WHO to conduct virtual cGMP for vaccine manufacturing
By IPP Bureau - September 08, 2021
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
RenovoRx receives New 510(k) clearance from US FDA
By IPP Bureau - September 08, 2021
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Giuliano Perfetti is the new CEO of Jubilant Biosys
By IPP Bureau - September 08, 2021
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
TCS leads in Life Sciences operations services: Everest group
By IPP Bureau - September 08, 2021
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Biocon settles suit with Celgene for generic Revlimid
By IPP Bureau - September 08, 2021
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Japan to purchase 150 million doses of Novavax’ Covid-19 vaccine from Takeda
By IPP Bureau - September 08, 2021
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Sun Pharma Consumer Healthcare launch Revital NXT nutrition bar
By IPP Bureau - September 08, 2021
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
Caplin Steriles gets US FDA approval for blood pressure injection
By IPP Bureau - September 08, 2021
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
Navitas Life Sciences acquires its 200th customer
By IPP Bureau - September 08, 2021
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
Metropolis Healthcare opens a new testing centre in Latur, Maharashtra
By IPP Bureau - September 08, 2021
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
